It seems we can’t find what you’re looking for. Perhaps searching can help.
- 3399
[] Institution:Study Staff Contact – [3399] Trial:A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers